Creative Commons source reading · Headache and migraine
Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
Andrew M Blumenfeld; Richard J Stark; Marshall C Freeman; Amelia Orejudos; Aubrey Manack Adams
Originally published in The journal of headache and pain · 2018-02-05
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Background OnabotulinumtoxinA is approved for the prevention of headache in those with chronic migraine (CM); however, more clinical data on the risk-benefit profile for treatment beyond one year is desirable. Methods The Chronic Migraine OnabotulinuMtoxinA Prolonged Efficacy open Label (COMPEL) Study ( ClinicalTrials.gov , NCT01516892) is an international, multicenter, open-label long-term prospective study. Adults with CM received 155 U of onabotulinumtoxinA (31 sites in a fixed-site, fixed-dose paradigm across 7 head/neck muscles) every 12 weeks (±7 days) for 9 treatment cycles (108 weeks). The primary outcome was headache day reductions at 108 weeks; secondary outcomes were headache day reductions at 60 weeks and change in the 6-item Headache Impact Test (HIT-6) score. Safety and tolerability were assessed by reviewing the frequency and nature of adverse events (AEs). AEs were determined at each visit through patient self-report, general non-directed and, for specific AEs, directed questioning, and physical examination.
Discussion
The COMPEL Study provides clinical evidence for consistency of the efficacy and long-term safety and tolerability for onabotulinumtoxinA for the prevention of headache in those with CM who have been treated every 12 weeks over 2 years (9 treatment cycles) with the fixed-site, fixed-dose injection paradigm. OnabotulinumtoxinA effectively reduced headache day frequency compared with baseline over 9 treatment cycles (108 weeks), improved HIT-6 scores and reduced moderate or severe headache day frequency.
Conclusions
The results of this international, multicenter, open-label, long-term prospective study support the efficacy and safety of onabotulinumtoxinA for prevention of headaches in adults with CM for up to 9 treatment cycles (108 weeks). Data indicated that onabotulinumtoxinA was effective in reducing headache days throughout 9 cycles of treatment, reducing the impact of headache from the first assessment (week 24). OnabotulinumtoxinA appeared to be well tolerated over 108 weeks and 9 cycles of treatment, and no new safety concerns were identified.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
